Published in

Karger Publishers, Ocular Oncology and Pathology, 2(4), p. 122-128, 2017

DOI: 10.1159/000479558

Links

Tools

Export citation

Search in Google Scholar

Dose Distributions and Treatment Margins in Ocular Brachytherapy with <sup>106</sup>Ru Eye Plaques

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Brachytherapy with <sup>106</sup>Ru eye plaques is the most common treatment modality for small to medium-sized uveal melanomas in Europe. So far, no standardized or widely accepted dose prescription protocol for the irradiation of intraocular tumors with <sup>106</sup>Ru eye plaques has been defined. For <sup>125</sup>I plaques, the minimum dose required for tumor control should be at least 85 Gy. Concerning <sup>106</sup>Ru plaques, the dose prescriptions at the University Hospital of Essen foresees minimum doses of 700 Gy to the tumor base and 130 Gy to the tumor apex. These dose prescriptions are expected to ensure sufficient treatment margins. We apply these dose prescriptions to different eye plaque types and tumor sizes and discuss the resulting treatment margins. These investigations are based on Monte Carlo simulations of dose distributions of 3 different eye plaque types. The treatment margin in apical direction has an expansion of at least 0.8 mm for all investigated eye plaques. For symmetrically formed eye plaques, the treatment margin at the base of the tumor goes beyond the visible edge of the plaque. This study focuses on the shape of 85-Gy isodose lines and on treatment margins for different eye plaque types and tumor sizes and shall help exchange knowledge for ocular brachytherapy.